metformin has been researched along with Graft-Versus-Host Disease in 5 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "GVHD had little effect." | 5.35 | O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease. ( Bernard, GR; Ely, EW; Harvey, SB; Homoncik, M; Jilma, B; Kasthuri, RS; Kellogg, TA; Lund, TC; Monkkonen, T; Nelsestuen, GL; Swan, T; Verneris, MR; Wilson-Grady, J; Zeisler, H; Zhang, Y, 2009) |
| "GVHD had little effect." | 1.35 | O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease. ( Bernard, GR; Ely, EW; Harvey, SB; Homoncik, M; Jilma, B; Kasthuri, RS; Kellogg, TA; Lund, TC; Monkkonen, T; Nelsestuen, GL; Swan, T; Verneris, MR; Wilson-Grady, J; Zeisler, H; Zhang, Y, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, SK | 1 |
| Park, MJ | 2 |
| Jhun, JY | 1 |
| Beak, JA | 1 |
| Choi, JW | 1 |
| Rye, JY | 1 |
| Jang, JW | 1 |
| Bae, SH | 1 |
| Yoon, SK | 1 |
| Choi, HJ | 1 |
| You, YK | 1 |
| Cho, ML | 2 |
| Choi, JY | 1 |
| Lee, SY | 1 |
| Moon, SJ | 1 |
| Son, HJ | 1 |
| Lee, SH | 1 |
| Kim, EK | 1 |
| Byun, JK | 1 |
| Shin, DY | 1 |
| Park, SH | 1 |
| Yang, CW | 1 |
| Harvey, SB | 1 |
| Zhang, Y | 1 |
| Wilson-Grady, J | 1 |
| Monkkonen, T | 1 |
| Nelsestuen, GL | 1 |
| Kasthuri, RS | 1 |
| Verneris, MR | 1 |
| Lund, TC | 1 |
| Ely, EW | 1 |
| Bernard, GR | 1 |
| Zeisler, H | 1 |
| Homoncik, M | 1 |
| Jilma, B | 1 |
| Swan, T | 1 |
| Kellogg, TA | 1 |
| Wędrychowicz, A | 1 |
| Ciechanowska, M | 1 |
| Stelmach, M | 1 |
| Starzyk, J | 1 |
| Rooney, DP | 1 |
| Ryan, MF | 1 |
5 other studies available for metformin and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Combination Treatment With Metformin and Tacrolimus Improves Systemic Immune Cellular Homeostasis by Modulating Treg and Th17 Imbalance.
Topics: Adolescent; Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cel | 2020 |
Metformin attenuates graft-versus-host disease via restricting mammalian target of rapamycin/signal transducer and activator of transcription 3 and promoting adenosine monophosphate-activated protein kinase-autophagy for the balance between T helper 17 an
Topics: Adenylate Kinase; Animals; Autophagy; Cell Differentiation; Cell Proliferation; Disease Models, Anim | 2016 |
O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease.
Topics: Adult; Aged; Apolipoprotein C-III; Bariatric Surgery; Biomarkers; Diabetes Mellitus; Female; Glycosi | 2009 |
Diabetes mellitus after allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Comorbidity; Diabetes Mellitus; Drug Therapy, Combination; Female; Graft vs Host Disease | 2013 |
Diabetes with partial lipodystrophy following sclerodermatous chronic graft vs. host disease.
Topics: Adolescent; Bone Marrow Transplantation; Diabetes Mellitus, Type 2; Female; Graft vs Host Disease; H | 2006 |